Padsevonil

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Drug-resistant Epilepsy

Conditions

Drug-resistant Epilepsy, Focal-Onset Seizures

Trial Timeline

Feb 12, 2018 → Jan 30, 2020

NCT ID

NCT03373383

About Padsevonil

Padsevonil is a phase 2 stage product being developed by UCB for Drug-resistant Epilepsy. The current trial status is completed. This product is registered under clinical trial identifier NCT03373383. Target conditions include Drug-resistant Epilepsy, Focal-Onset Seizures.

What happened to similar drugs?

1 of 2 similar drugs in Drug-resistant Epilepsy were approved

Approved (1) Terminated (2) Active (0)

✅OnabotulinumtoxinA 145 UNT [Botox]AbbVieApproved

❌Padsevonil + PlaceboUCBPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04136444	Phase 1	Terminated	Oct 28, 2019	May 22, 2020	Healthy Study Participants
NCT04075409	Phase 1	Completed	Sep 30, 2019	Dec 27, 2019	Healthy Japanese Participants
NCT04013191	Phase 1	Completed	Jul 9, 2019	Oct 3, 2019	Elderly Study Participants
NCT03370120	Phase 2	Terminated	Aug 27, 2018	Dec 11, 2020	Drug-Resistant Epilepsy
NCT03373383	Phase 2	Completed	Feb 12, 2018	Jan 30, 2020	Drug-resistant Epilepsy

Competing Products

6 competing products in Drug-resistant Epilepsy

See all competitors

Product	Company	Stage	Hype Score
OnabotulinumtoxinA 145 UNT [Botox]	AbbVie	Approved	35
Delamanid + Levofloxacin + Bedaquiline + Clofazimine + Linezolid	Novartis	Phase 2	42
UCB0942	UCB	Phase 2	27
Padsevonil + Placebo	UCB	Phase 3	32
Padsevonil	UCB	Phase 2	27
UCB0942 + UCB0942 + Placebo	UCB	Phase 2	35